ACOR Financial Facts
Provision for income taxes: -3.02MTotal operating expenses: 141.09M
See Full Income Statement
Total assets: 1.32B
Non-current portion of convertible notes payable: 0
See Full Balance Sheet
Acorda Therapeutics, Inc. (ACOR) Earnings
|
Expand Research on ACOR
| Next EPS Date | N/A | EPS Growth Rate | -139.7% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | -188.2% | Revenue Growth Rate | +63.1% *Last Qtr. |
| Average % Move 1-Wk after EPS | -8.4% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
8/8/23  |
Q223 | -$7.55 | N/A | N/A | $29.68M | N/A | N/A |  | | Details | |
| 5/4/23 | Q123 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
| 5/11/23 | Q123 | -$0.69 | N/A | N/A | $22.25M | N/A | N/A | | | Details | |
| 2/16/23 | Q422 | N/A | -$0.15 | N/A | N/A | $35M | N/A | N/A | N/A | ||
| 2/27/23 | Q422 | N/A | -$0.15 | N/A | N/A | $35M | N/A | N/A | N/A | ||
| 2/20/23 | Q422 | N/A | -$0.15 | N/A | N/A | $35M | N/A | N/A | N/A | ||
| 3/6/23 | Q422 | N/A | -$0.15 | N/A | N/A | $35M | N/A | N/A | N/A | ||
| 3/9/23 | Q422 | N/A | -$0.15 | N/A | N/A | $35M | N/A | N/A | N/A |
